$1.90
-3.06%SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Quality against peers; 50 is the peer median.
Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.